Lu Qijue, Ma Ye, An Zhao, Zhao Tiejun, Xu Zhiyun, Chen Hezhong
Department of Cardiothoracic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
J Thorac Dis. 2018 Nov;10(11):6030-6039. doi: 10.21037/jtd.2018.10.19.
We aimed to investigate the impact of epidermal growth factor receptor (EGFR) mutation in the progression of lung adenocarcinoma presented as a solitary ground-glass opacity (GGO) by retrospectively evaluating the correlation between EGFR mutation status and the radiographic features.
One hundred fifty-six cases of lung adenocarcinoma presented as a solitary GGO were enrolled between 2013 and 2015. Chest CT scans were performed 3 times (1st ≥3 months, 2nd ≤1 week preoperatively and 3rd ≥3 months postoperatively) in each patient. The diameter and volume of every lesion was measured by semiautomated algorithm. EGFR mutation hotspots from exons 18, 19 and 21 were detected by real-time PCR.
In the 156 patients who were enrolled in our study, tumors in 75 patients (48.1%) were pathologically diagnosed with EGFR-mutant, with 1, 29 and 45 cases harboring tumors with mutation in exon 18, 19 and 21, respectively. EGFR mutation occurred more frequently in women (P=0.005) and non-smokers (P=0.019). Comparison between the 1st and 2nd preoperative CT scans showed that 28 (37.3%) of 75 patients with EGFR mutations had an over 50% increment of tumor size and 38 (52.0%) displayed a growth of solid component. On the other hand, we found only 9 (11.1%) and 14 (17.3%) in 81 lesions without EGFR mutation had a distinct volume growth and component solidification, respectively, which is significantly less than that in EGFR mutation lesions (P<0.001). Further, in the postoperative CT scan, recurrent GGOs or nodes were identified in 6 (8%) EGFR-mutant patients and 6 (7.4%) in wild-type patients (P=0.89), which indicates no overt statistically difference. At last, we found that EGFR amplification is more frequent as GGO volume percentage decreases and diameter increases.
We found GGOs with EGFR mutation grew faster in volume and solidified more quickly in component than wild-type GGOs. Moreover, in the follow-up after surgery, patients in the EGFR mutation group and EGFR wild-type group showed no significant difference in the imaging evolvement.
我们旨在通过回顾性评估表皮生长因子受体(EGFR)突变状态与影像学特征之间的相关性,来研究EGFR突变在表现为孤立性磨玻璃影(GGO)的肺腺癌进展中的影响。
纳入2013年至2015年间156例表现为孤立性GGO的肺腺癌患者。每位患者均进行3次胸部CT扫描(第1次≥3个月,第2次在术前≤1周,第3次在术后≥3个月)。采用半自动算法测量每个病灶的直径和体积。通过实时PCR检测外显子18、19和21的EGFR突变热点。
在我们纳入研究的156例患者中,75例(48.1%)患者的肿瘤经病理诊断为EGFR突变型,其中外显子18、19和21发生突变的肿瘤分别有1例、29例和45例。EGFR突变在女性(P = 0.005)和非吸烟者(P = 0.019)中更常见。第1次和第2次术前CT扫描结果比较显示,75例EGFR突变患者中有28例(37.3%)肿瘤大小增加超过50%,38例(52.0%)出现实性成分生长。另一方面,我们发现81例无EGFR突变的病灶中,分别仅有9例(11.1%)体积明显增大,14例(17.3%)出现成分实性化,显著低于EGFR突变病灶(P < 0.001)。此外,在术后CT扫描中,6例(8%)EGFR突变患者和6例(7.4%)野生型患者发现复发性GGO或结节(P = 0.89),表明无明显统计学差异。最后,我们发现随着GGO体积百分比降低和直径增加,EGFR扩增更常见。
我们发现EGFR突变的GGO比野生型GGO体积增长更快,成分实性化更快。此外,在术后随访中,EGFR突变组和EGFR野生型组患者在影像学演变方面无显著差异。